Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares

Liminatus Pharma, Inc.

Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.
Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.
New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.
Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.
Net proceeds from the exercise will be used for working capital and general corporate purposes.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Liminatus Pharma, Inc. issued warrants to purchase an aggregate of up to 20,688,000 shares of common stock of warrant to a holder (the "Holder") of its existing common stock warrants for aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,920.00.

Security: warrant
Shares: warrants to purchase an aggregate of up to 20,688,000 shares of common stock
Purchaser: a holder (the "Holder") of its existing common stock warrants
Consideration: aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,920.00

Exact text from the filing

Warrants” and, together with the New Black-Scholes Warrants, the “Inducement Warrants”). The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,920.00, before deducting financial advisory fees. The Company intends to use the net proceeds from the exercise of the Existing Warrants for working capital and general corporate

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).

Action: entry
Agreement: equity purchase
Counterparty: a holder of its existing common stock warrants
Value: $1,861,920.00
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants

View on SEC.gov

Browse all equity issuances →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-070173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.